GammaCan, Life Therapeutics to develop melanoma therapy VitiGam

By Elaine Rigoli

Tampa, Fla., Aug. 22 - GammaCan International and Life Therapeutics said they will collaborate to develop VitiGam, an anticancer product designed to target metastatic malignant melanoma patients with stage 3 and 4 disease.

Under the agreement, the partners will share the costs and expenses relating to the development, supply, collection, manufacture, storage and commercialization of VitiGam as well as their respective portion in any proceeds resulting of the collaboration.

Life Therapeutics will also supply plasma to GammaCan for this project.

Other terms of the agreement were not disclosed.

GammaCan, located in Kiryat Ono, Israel, is a biopharmaceutical company.

Life Therapeutics is a biopharmaceutical company based in Atlanta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.